丹红注射液对冠心病患者阿司匹林反应单位和临床预后的影响

发布时间：2018-06-12 03:44

本文选题：冠心病 + 阿司匹林抵抗　；参考：《中华中医药学刊》2017年05期

【摘要】：目的:探讨丹红注射液对冠心病合并阿司匹林抵抗患者阿司匹林反应单位(aspirin reaction units,ARU)和临床预后的影响。方法:自2012年1月—2014年1月,前瞻性收集冠心病合并阿司匹林抵抗患者100例,将患者随机分为研究组(n=50)和对照组(n=50)。研究组在常规治疗的基础上,联合使用丹红注射液治疗;对照组仅采用常规治疗。主要观察指标为两组患者ARU和临床预后。结果:两组患者入院时ARU和血小板聚集率差异无统计学意义(P0.05)。与对照组比较,治疗后研究组ARU水平显著降低(540.39±54.39 vs.654.49±39.48,P=00);血小板聚集率显著降低[(49.59±9.48)%vs.(64.39±8.89)%,P=00)];再次入院率显著降低(20%vs.40%,P=29)。死亡率、非致死性心梗、卒中和出血发生率等均无统计学意义(P0.05)。结论:丹红注射液有助于降低阿司匹林抵抗患者ARU,降低再入院率。
[Abstract]:Objective: To investigate the effect of Danhong Injection on aspirin reaction units (ARU) and clinical prognosis in patients with coronary heart disease and aspirin resistance. Methods: from January 2012 to January 2014, 100 patients with coronary heart disease combined with aspirin resistance were prospectively collected, and the patients were randomly divided into study group (n=50) and control group (n=50). The study group was treated with Danhong Injection on the basis of routine treatment. The control group was only treated with routine treatment. The main observation index was two groups of patients with ARU and clinical prognosis. Results: there was no significant difference in the ARU and platelet aggregation rate in the two groups (P0.05). Compared with the group, the level of ARU in the study group was significantly lower (54). 0.39 + 54.39 vs.654.49 + 39.48, P=00), platelet aggregation rate decreased significantly [(49.59 + 9.48)%vs. (64.39 + 8.89)%, P=00)], and the readmission rate was significantly decreased (20%vs.40%, P=29). Mortality, non lethal myocardial infarction, stroke and bleeding incidence were not statistically significant (P0.05). Conclusion: Danhong injection helps to reduce ARU in aspirin resistance patients. Reduce reentry rate.
【作者单位】：宁波市第一医院心血管内科;宁波市中医院心血管内科;
【基金】：浙江省中医药科学研究基金计划项目(2010ZB127)
【分类号】：R259

【相似文献】